TIL therapy

TIL therapy

Oncology An experimental CA therapy in which antigen-
specific tumor-infiltrating T lymphocytes–TILs are isolated from biopsies of Pts with CA and co-administered with IL-2. Cf LAK/IL-2 therapy.
Mentioned in ?
References in periodicals archive ?
Food and Drug Administration, the FDA has acknowledged that the ongoing innovaTIL-04 study of TIL therapy LN-145 may be sufficient to support registration in the treatment of patients with advanced cervical cancer.
Iovance CEO sees path for LN-145 BLA submission in 2H20 following FDA meeting
The 22-day Iovance Gen 2 TIL therapy process is robust and scalable, and has led to impressive responses in melanoma, cervical and head and neck indications, commented Maria Fardis, Ph.D., M.B.A., president and chief executive officer of Iovance.
United States : Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products
The general procedure for autologous TIL therapy is stated as follows: (1) the resected melanoma is digested into fragments; (2) each fragment is grown in IL-2 and the lymphocytes proliferate destroying the tumor; (3) after a pure population of lymphocytes exists, these lymphocytes are expanded; and (4) after expansion up to 1011 cells, lymphocytes are infused into the patient (Figure 2(a)) [66].
Immunotherapies: Exploiting the Immune System for Cancer Treatment
TIL therapy is being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center.
Lion Biotechnologies submits Investigational New Drug Application with US FDA for cervical, head and neck cancer
The terminal cancer patients won't benefit directly from the genetic manipulation, but may benefit from the TIL therapy, which can shrink tumors.
Gene-transfer trial begins in humans
Iovance Biotherapeutics announced updated data from studies of TIL therapy LN-145 in patients with advanced cervical cancer and TIL therapy lifileucel in advanced melanoma.
Iovance Biotherapeutics announces updated data from LN-145 study
After TIL therapy, ipilimumab was given to 3 patients who responded: patient 5: PR then SD; patient 7: early PR then progression; and patient 10: SD.
Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
In this role, he was instrumental in driving the company s metastatic melanoma TIL program into clinical development in the first TIL therapy trial performed outside an academic center.
Germany : Merck Appoints Laszlo Radvanyi as Head of Global Immuno-Oncology Research
TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center.
Lion Biotechnologies awarded US FDA's orphan drug status for LN-144 for malignant melanoma
Iovance Biotherapeutics announced an update to its clinical programs with TIL therapy in the treatment of cervical cancer and non-small cell lung cancer, or NSCLC.
Iovance Biotherapeutics to close IOV-LUN-201 study, add arm to IOV-COM-202 study
For a long time, TIL therapy had already shown promise for advanced melanoma patients, with 51% to 72% ORR by Rosenberg et al.
Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-[alpha] in Chinese Resected Stage III Malignant Melanoma
Having exclusivity meaningfully de-risks our development and commercialisation efforts, putting us in an even stronger position to investigate TIL therapy in the treatment of metastatic melanoma.'
Lion Biotechnologies receives license for patents to develop tumour-infiltrating lymphocytes therapy

Medical browser ?
Full browser ?